Hengrui Pharmaceuticals Gains NMPA Approval for HRS9531 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Huadong Medicine Files for NMPA Approval of Ranibizumab Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market approval filing for a...
Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...
CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough...
Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...
Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting
Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...
Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting
China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...
BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies
China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million...
Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy
Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced...
Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...
Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...
R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease
Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...
GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...
Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...
Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...
MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
MSD Appoints Kyle Tattle as President of China Operations
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...
Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...